© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to February
mechanism-based SAE E1 ligase inhibitor
first-in-class, Ph. II (IV) for adv. solid tumors
from phenotypic screen and scaffold hop
J. Med. Chem., Feb. 25, 2021
Millenium/Takeda, Cambridge, MA
5. The Millenium/Takeda SUMO-activating enzyme (SAE) inhibitor TAK-981 is a mechanism-based inhibitor that covalently forms a SUMO substrate-inhibitor adduct that potently inhibits SAE, rather than reacting with SAE directly.…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.